NORTH AMERICA RAT MODEL MARKET FORECAST 2017- 2025
KEY FINDINGS
The North-America market is growing at a CAGR of 9.61% for the forecast period of 2017-2025 and is anticipated to generate a revenue of $408900 thousand by 2025.The North-American market is expected to hold the lion’s share in the rat model market by the end of the forecast period. The novel discoveries in the methodologies for monoclonal antibodies production, a growing demand for personalized medicines and the subsequent rise in demand for various rat models for research activities are some of the factors which are providing the North-American rat model market with excellent growth opportunities.
MARKET INSIGHTS
Various aspects like new and improved genome editing techniques, increasing research by biotechnological and bio-pharmaceutical companies and ease of access for the rat transgenic methodologies are acting as the major drivers for the market. The rat model market segmentation depends on various factors like the type of rat models (inbred, knock-out, hybrid, outbred etc), on the type of components; which includes the technology used, the service provided and the various rat care products needed during the research, and also on the basis of the application of the models in various medical and research fields. The United States has shown the highest growth in the North American region and is expected to continue its dominance over the forecasted period.
COMPETITIVE INSIGHTS
Because of the presence of major pharmaceutical companies like Roche, Merck & Co., and Novartis in the North American region and their main focus being on pre-clinical trials and clinical research studies, the demand for the rat models have increased considerably in the U.S. Also, Lab Corp is another such company in the North American market which is now primarily focusing on genomic study. The other companies currently on the North American rat model market scene are Oncodesign S.A, Biomedical Research Vivo Biotech Ltd ,Cyagen Biosciences Inc , Charles River Laboratories Inc Harlan Laboratories, Inc. (Envigo, Inc. Holding Company), Model Inc,.Sage Labs Inc(Horizon Discovery Group Plc Holding Company), Genoway S. A, , Janvier Labs, Transviragen Inc, Hera Biolabs Inc, Biomere, Vivo Biotech Ltd, Clea Japan, Transviragen, Inc. Taconic Biosciences, Laboratory Corporation Of America Holdings and Transposagen Biopharmaceuticals Inc.
The North-America market is growing at a CAGR of 9.61% for the forecast period of 2017-2025 and is anticipated to generate a revenue of $408900 thousand by 2025.The North-American market is expected to hold the lion’s share in the rat model market by the end of the forecast period. The novel discoveries in the methodologies for monoclonal antibodies production, a growing demand for personalized medicines and the subsequent rise in demand for various rat models for research activities are some of the factors which are providing the North-American rat model market with excellent growth opportunities.
MARKET INSIGHTS
Various aspects like new and improved genome editing techniques, increasing research by biotechnological and bio-pharmaceutical companies and ease of access for the rat transgenic methodologies are acting as the major drivers for the market. The rat model market segmentation depends on various factors like the type of rat models (inbred, knock-out, hybrid, outbred etc), on the type of components; which includes the technology used, the service provided and the various rat care products needed during the research, and also on the basis of the application of the models in various medical and research fields. The United States has shown the highest growth in the North American region and is expected to continue its dominance over the forecasted period.
COMPETITIVE INSIGHTS
Because of the presence of major pharmaceutical companies like Roche, Merck & Co., and Novartis in the North American region and their main focus being on pre-clinical trials and clinical research studies, the demand for the rat models have increased considerably in the U.S. Also, Lab Corp is another such company in the North American market which is now primarily focusing on genomic study. The other companies currently on the North American rat model market scene are Oncodesign S.A, Biomedical Research Vivo Biotech Ltd ,Cyagen Biosciences Inc , Charles River Laboratories Inc Harlan Laboratories, Inc. (Envigo, Inc. Holding Company), Model Inc,.Sage Labs Inc(Horizon Discovery Group Plc Holding Company), Genoway S. A, , Janvier Labs, Transviragen Inc, Hera Biolabs Inc, Biomere, Vivo Biotech Ltd, Clea Japan, Transviragen, Inc. Taconic Biosciences, Laboratory Corporation Of America Holdings and Transposagen Biopharmaceuticals Inc.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. IMPROVEMENT IN GENOME EDITING
4.1.2. FAST AND INCREASING AVAILABILITY IN RAT TRANSGENIC
4.1.3. INCREASING PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES R&D
4.2. MARKET RESTRAINTS
4.2.1. PRACTICE OF ANIMALS IN RESEARCH IS CONSIDERED UNETHICAL
4.2.2. FLUCTUATING RULES AND REGULATION ON ANIMAL TESTING
4.2.3. USE OF ZEBRA FISH IN RESEARCH IS THE GROWING MODEL
4.2.4. IN VITRO AND ALTERNATIVE TESTING TECHNIQUES MODELS FOR RESEARCH
4.3. MARKET OPPORTUNITIES
4.3.1. RISING DEMAND OF RAT MODEL FOR RESEARCH ACTIVITIES FROM EMERGENT ECONOMIES
4.3.2. PERSONALIZED MEDICINE ESTABLISHED TO SURGE DEMAND
4.3.3. ESCALATION IN MONOCLONAL ANTIBODY CREATION
4.4. MARKET CHALLENGES
4.4.1. RAT MODEL IS HIGHLY EXPENSIVE
5. MARKET SEGMENTATION
5.1. BY RAT MODEL TYPES
5.1.1. INBRED RATS
5.1.2. KNOCKOUT/GENETICALLY ENGINEERED RATS
5.1.3. HYBRID/CONGENIC RATS
5.1.4. OUTBRED RATS
5.1.5. IMMUNE-DEFICIENT RATS
5.1.6. CONDITIONED/SURGICALLY MODIFIED RATS
5.2. BY COMPONENTS
5.2.1. TECHNOLOGY
5.2.1.1. NUCLEAR TRANSFERASE TECHNOLOGY
5.2.1.2. MICROINJECTION
5.2.1.3. EMBRYONIC STEM CELL INJECTION
5.2.1.4. OTHER TECHNOLOGY
5.2.2. SERVICES
5.2.3. RAT CARE PRODUCTS
5.2.3.1. FEED
5.2.3.2. BEDDING
5.2.3.3. CAGES
5.2.3.4. OTHER CARE PRODUCTS
5.3. BY APPLICATION
5.3.1. DIABETES
5.3.2. TOXICOLOGY
5.3.3. ONCOLOGY
5.3.4. IMMUNOLOGY & INFLAMMATION
5.3.5. OTHER
6. KEY ANALYTICS
6.1. PORTERS 5 FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCT
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. VALUE CHAIN ANALYSIS
6.4. OPPORTUNITY MATRIX
6.5. REGULATORY FRAMEWORK
6.6. ESTIMATION ANALYSIS
6.6.1. GLOBAL BIOTECH INVESTMENT
6.6.2. BIOTECHNOLOGY FIRMS ACROSS COUNTRIES
6.6.3. GLOBAL PHARMACEUTICAL RESEARCH & DEVELOPMENT EXPENDITURE
6.6.4. GLOBAL BIOTECH R&D EXPENDITURE
6.7. KEY BUYING CRITERIA
6.7.1. HIGH ACCURACY
6.7.2. HIGH EFFICACY
6.7.3. QUALITY OF OPERATING PROCEDURE
6.7.4. PRICE
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. U.S.
7.1.2. CANADA
8. COMPETITIVE ANALYSIS
8.1. KEY STRATEGIES AND ANALYSIS
8.1.1. MERGER & ACQUISITION (M&A)
8.1.2. COLLABORATION & PARTNERSHIPS
8.1.3. INVESTMENT / PRODUCT LAUNCH
8.2. MARKET SHARE
8.3. TOP COMPANY ANALYSIS
8.4. LIST OF M&A
8.5. COLLABORATION & PARTNERSHIP
8.6. LIST OF PRODUCT LAUNCHES
9. COMPANY PROFILE
9.1. BIOMEDICAL RESEARCH MODEL INC.
9.1.1. COMPANY OVERVIEW
9.1.2. PRODUCT PORTFOL
9.1.3. SCOT ANALYSIS
9.2. CHARLES RIVER LABORATORIES INC.
9.2.1. COMPANY OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. KEY INNOVATION SECTOR
9.2.4. STRATEGIC INITIATIVES
9.2.5. SCOT ANALYSIS
9.3. COVANCE INC. (LABCORP HOLDING COMPANY)
9.3.1. COMPANY OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. KEY INNOVATION SECTOR
9.3.4. STRATEGIC INITIATIVES
9.3.5. SCOT ANALYSIS
9.4. GENOWAY S. A.
9.4.1. COMPANY OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. KEY INNOVATION SECTOR
9.4.4. STRATEGIC INITIATIVES
9.4.5. SCOT ANALYSIS
9.5. HARLAN LABORATORIES, INC. (ENVIGO, INC. HOLDING COMPANY)
9.5.1. COMPANY OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC INITIATIVES
9.5.4. SCOT ANALYSIS
9.6. JANVIER LABS
9.6.1. COMPANY OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. SAGE LABS INC(HORIZON DISCOVERY GROUP PLC HOLDING COMPANY)
9.7.1. COMPANY OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC INITIATIVES
9.7.4. SCOT ANALYSIS
9.8. TACONIC BIOSCIENCES
9.8.1. COMPANY OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. KEY INNOVATION SECTOR
9.8.4. STRATEGIC INITIATIVES
9.8.5. SCOT ANALYSIS
9.9. TRANSPOSAGEN BIOPHARMACEUTICALS INC
9.9.1. COMPANY OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. KEY INNOVATION SECTOR
9.9.4. STRATEGIC INITIATIVES
9.9.5. SCOT ANALYSIS
9.10. TRANSVIRAGEN INC.
9.10.1. COMPANY OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.11. HERA BIOLABS INC.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. KEY INNOVATION SECTOR
9.11.4. STRATEGIC INITIATIVE
9.11.5. SCOT ANALYSIS
9.12. ONCODESIGN S.A.
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. KEY INNOVATION SECTOR
9.12.4. STRATEGIC INITIATIVE
9.12.5. SCOT ANALYSIS
9.13. CYAGEN BIOSCIENCES INC.
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. KEY INNOVATION SECTOR
9.13.4. STRATEGIC INITIATIVE
9.13.5. SCOT ANALYSIS
9.14. VIVO BIOTECH LTD.
9.14.1. COMPANY OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. STRATEGIC INITIATIVES
9.14.4. SCOT ANALYSIS
9.15. CLEA JAPAN
9.15.1. COMPANY OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. STRATEGIC INITIATIVES
9.15.4. KEY INNOVATION SECTOR
9.15.5. SCOT ANALYSIS
9.16. TRANSVIRAGEN, INC.
9.16.1. COMPANY OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. STRATEGIC INITIATIVES
9.16.4. KEY INNOVATION SECTOR
9.16.5. SCOT ANALYSIS
9.17. BIOMERE
9.17.1. COMPANY OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. STRATEGIC INITIATIVES
9.17.4. KEY INNOVATION SECTOR
9.17.5. SCOT ANALYSIS
9.18. LABORATORY CORPORATION OF AMERICA HOLDINGS
9.18.1. COMPANY OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. STRATEGIC INITIATIVES
9.18.4. KEY INNOVATION SECTOR
9.18.5. SCOT ANALYSIS
TABLE LIST
TABLE 1 NORTH AMERICA RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 2 BENEFITS OF RAT
TABLE 3 NORTH AMERICA RAT MODEL MARKET BY RAT TYPES 2017-2025 ($ THOUSAND)
TABLE 4 EXAMPLES OF INBRED RAT AND THERE RESEARCH APPLICATIONS
TABLE 5 NORTH AMERICA INBRED RAT TYPE 2017-2025 ($ THOUSAND)
TABLE 6 NORTH AMERICA GENETICALLY ENGINEERED RAT MARKET 2017-2025($ THOUSAND)
TABLE 7 NORTH AMERICA HYBRID RAT MARKET 2017-2025 ($ THOUSAND)
TABLE 8 EXAMPLES OF OUTBRED RAT AND THERE RESEARCH APPLICATIONS
TABLE 9 NORTH AMERICA OUTBRED RAT MARKET 2017-2025 ($ THOUSAND)
TABLE 10 NORTH AMERICA IMMUNE DEFICIT RAT MARKET 2017-2025 ($ THOUSAND)
TABLE 11 NORTH AMERICA SURGICALLY MODIFIED RAT MARKET 2017-2025 ($ THOUSAND)
TABLE 12 NORTH AMERICA RAT MODEL MARKET BY COMPONENTS 2017-2025 ($ THOUSAND)
TABLE 13 NORTH AMERICA RAT MODEL MARKET BY TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 14 NORTH AMERICA NUCLEAR TRANSFER TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 15 NORTH AMERICA MICRO INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 16 NORTH AMERICA EMBRYONIC STEM CELL INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 17 NORTH AMERICA OTHER TECHNOLOGY RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 18 NORTH AMERICA RAT MODEL SERVICES MARKET 2017-2025 ($ THOUSAND)
TABLE 19 NORTH AMERICA RAT MODEL MARKET BY RAT CARE PRODUCTS 2017-2025 ($ THOUSAND)
TABLE 20 NORTH AMERICA RAT FEED MARKET 2017-2025 ($ THOUSAND)
TABLE 21 POPULAR FOODS FOR RAT
TABLE 22 NORTH AMERICA RAT BEDDING MARKET 2017-2025 ($ THOUSAND)
TABLE 23 NORTH AMERICA RAT CAGES MARKET 2017-2025 ($ THOUSAND)
TABLE 24 NORTH AMERICA RAT CARE OTHERS MARKET 2017-2025 ($ THOUSAND)
TABLE 25 NORTH AMERICA RAT MODEL MARKET BY APPLICATION 2017-2025($ THOUSAND)
TABLE 26 NORTH AMERICA DIABETES RAT MODEL MARKET 2017-2025($ THOUSAND)
TABLE 27 NORTH AMERICA ONCOLOGY RAT MODEL MARKET 2017-2025($ THOUSAND)
TABLE 28 NORTH AMERICA IMMUNOLOGY & INFLAMMATION RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 29 NORTH AMERICA OTHER RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 30 NORTH AMERICA RAT MODEL MARKET 2017-2025 ($ MILLION)
TABLE 31 NORTH AMERICA RAT MODEL MARKET BY COUNTRY 2017-2025 ($ MILLION)
TABLE 32 BUDGET AUTHORITY BY ACTIVITY IN THE U.S. 2015-2017 ($ MILLION)
FIGURES LIST
FIGURE 1 NORTH AMERICA RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 2 NUMBER OF EXPERIMENTAL PROCEDURES OF ANIMALS IN U.S. IN 2016
FIGURE 3 TOP COMPANIES BASED ON IN VITRO DIAGNOSTICS REVENUE IN 2016 ($ MILLION)
FIGURE 4 NORTH AMERICA RAT MODEL MARKET BY INBRED RAT TYPE 2017-2025 ($ THOUSAND)
FIGURE 5 NORTH AMERICA RAT MODEL MARKET BY GENETICALLY ENGINEERED RAT 2017-2025 ($ THOUSAND)
FIGURE 6 NORTH AMERICA RAT MODEL MARKET BY HYBRID RAT TYPE 2017-2025 ( $ THOUSAND)
FIGURE 7 NORTH AMERICA RAT MODEL MARKET BY OUTBRED RAT 2017-2025 ($ THOUSAND)
FIGURE 8 NORTH AMERICA RAT MODEL MARKET BY IMMUNE DEFICIENT RAT 2017-2025 ($ THOUSAND)
FIGURE 9 NORTH AMERICA RAT MODEL MARKET BY SURGICALLY MODIFIED RAT 2017-2025 ($ THOUSAND)
FIGURE 10 NORTH AMERICA RAT MODEL MARKET BY TECHNOLOGY 2017-2025 ($ THOUSANDS)
FIGURE 11 NORTH AMERICA RAT MODEL MARKET BY NUCLEAR TRANSFER TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 12 NORTH AMERICA RAT MODEL MARKET BY MICRO INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 13 NORTH AMERICA RAT MODEL MARKET BY EMBRYONIC STEM CELL INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 14 NORTH AMERICA RAT MODEL MARKET BY OTHER TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 15 RAT CARE PRODUCTS BY TYPE 2016 (%)
FIGURE 16 NORTH AMERICA RAT CARE PRODUCT MARKET BY FEED 2017-2025 ($ THOUSAND)
FIGURE 17 NORTH AMERICA RAT CARE PRODUCT MARKET BY BEDDING 2017-2025 ($ THOUSAND)
FIGURE 18 NORTH AMERICA RAT CARE PRODUCT MARKET BY CAGES 2017-2025 ($ THOUSAND)
FIGURE 19 NORTH AMERICA RAT MODEL MARKET BY DIABETES 2017-2025($ THOUSAND)
FIGURE 20 PERCENTAGE OF DIABETES IN WORLD ADULT POPULATION IN 1980, 2015 AND 2040
FIGURE 21 NORTH AMERICA RAT MODEL MARKET BY TOXICOLOGY 2017-2025($ THOUSAND)
FIGURE 22 NORTH AMERICA TOXICOLOGY RAT MODEL MARKET 2017-2025($ THOUSAND)
FIGURE 23 NORTH AMERICA RAT MODEL MARKET BY ONCOLOGY 2017-2025($ THOUSAND)
FIGURE 24 INCREASING COSTS OF ONCOLOGY THERAPEUTICS AND SUPPORTIVE CARE DRUGS ($ BILLION)
FIGURE 25 NORTH AMERICA RAT MODEL MARKET BY IMMUNOLOGY & INFLAMMATION 2017-2025 ($ THOUSAND)
FIGURE 26 NORTH AMERICA RAT MODEL MARKET BY OTHER 2017-2025 ($ THOUSAND)
FIGURE 27 PORTERS 5 FORCE MODEL OF RAT MODEL
FIGURE 28 NORTH AMERICA RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 29 NATIONAL HUMAN GENOME RESEARCH BUDGET, 2017 ($ MILLION)
FIGURE 30 U.S. PHARMACEUTICAL INDUSTRY EXPENDITURE ON R&D 2012-2015 ($ BILLION)
FIGURE 31 U.S. RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 32 FUNDS ALLOCATED FOR RESEARCH ACTIVITIES IN BUDGET 2016
FIGURE 33 CANADIAN PHARMACEUTICAL MARKET 2015 & 2020 ($ BILLION)
FIGURE 34 CANADA RAT MODEL MARKET 2017-2025 ($THOUSAND)
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. IMPROVEMENT IN GENOME EDITING
4.1.2. FAST AND INCREASING AVAILABILITY IN RAT TRANSGENIC
4.1.3. INCREASING PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES R&D
4.2. MARKET RESTRAINTS
4.2.1. PRACTICE OF ANIMALS IN RESEARCH IS CONSIDERED UNETHICAL
4.2.2. FLUCTUATING RULES AND REGULATION ON ANIMAL TESTING
4.2.3. USE OF ZEBRA FISH IN RESEARCH IS THE GROWING MODEL
4.2.4. IN VITRO AND ALTERNATIVE TESTING TECHNIQUES MODELS FOR RESEARCH
4.3. MARKET OPPORTUNITIES
4.3.1. RISING DEMAND OF RAT MODEL FOR RESEARCH ACTIVITIES FROM EMERGENT ECONOMIES
4.3.2. PERSONALIZED MEDICINE ESTABLISHED TO SURGE DEMAND
4.3.3. ESCALATION IN MONOCLONAL ANTIBODY CREATION
4.4. MARKET CHALLENGES
4.4.1. RAT MODEL IS HIGHLY EXPENSIVE
5. MARKET SEGMENTATION
5.1. BY RAT MODEL TYPES
5.1.1. INBRED RATS
5.1.2. KNOCKOUT/GENETICALLY ENGINEERED RATS
5.1.3. HYBRID/CONGENIC RATS
5.1.4. OUTBRED RATS
5.1.5. IMMUNE-DEFICIENT RATS
5.1.6. CONDITIONED/SURGICALLY MODIFIED RATS
5.2. BY COMPONENTS
5.2.1. TECHNOLOGY
5.2.1.1. NUCLEAR TRANSFERASE TECHNOLOGY
5.2.1.2. MICROINJECTION
5.2.1.3. EMBRYONIC STEM CELL INJECTION
5.2.1.4. OTHER TECHNOLOGY
5.2.2. SERVICES
5.2.3. RAT CARE PRODUCTS
5.2.3.1. FEED
5.2.3.2. BEDDING
5.2.3.3. CAGES
5.2.3.4. OTHER CARE PRODUCTS
5.3. BY APPLICATION
5.3.1. DIABETES
5.3.2. TOXICOLOGY
5.3.3. ONCOLOGY
5.3.4. IMMUNOLOGY & INFLAMMATION
5.3.5. OTHER
6. KEY ANALYTICS
6.1. PORTERS 5 FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCT
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. VALUE CHAIN ANALYSIS
6.4. OPPORTUNITY MATRIX
6.5. REGULATORY FRAMEWORK
6.6. ESTIMATION ANALYSIS
6.6.1. GLOBAL BIOTECH INVESTMENT
6.6.2. BIOTECHNOLOGY FIRMS ACROSS COUNTRIES
6.6.3. GLOBAL PHARMACEUTICAL RESEARCH & DEVELOPMENT EXPENDITURE
6.6.4. GLOBAL BIOTECH R&D EXPENDITURE
6.7. KEY BUYING CRITERIA
6.7.1. HIGH ACCURACY
6.7.2. HIGH EFFICACY
6.7.3. QUALITY OF OPERATING PROCEDURE
6.7.4. PRICE
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. U.S.
7.1.2. CANADA
8. COMPETITIVE ANALYSIS
8.1. KEY STRATEGIES AND ANALYSIS
8.1.1. MERGER & ACQUISITION (M&A)
8.1.2. COLLABORATION & PARTNERSHIPS
8.1.3. INVESTMENT / PRODUCT LAUNCH
8.2. MARKET SHARE
8.3. TOP COMPANY ANALYSIS
8.4. LIST OF M&A
8.5. COLLABORATION & PARTNERSHIP
8.6. LIST OF PRODUCT LAUNCHES
9. COMPANY PROFILE
9.1. BIOMEDICAL RESEARCH MODEL INC.
9.1.1. COMPANY OVERVIEW
9.1.2. PRODUCT PORTFOL
9.1.3. SCOT ANALYSIS
9.2. CHARLES RIVER LABORATORIES INC.
9.2.1. COMPANY OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. KEY INNOVATION SECTOR
9.2.4. STRATEGIC INITIATIVES
9.2.5. SCOT ANALYSIS
9.3. COVANCE INC. (LABCORP HOLDING COMPANY)
9.3.1. COMPANY OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. KEY INNOVATION SECTOR
9.3.4. STRATEGIC INITIATIVES
9.3.5. SCOT ANALYSIS
9.4. GENOWAY S. A.
9.4.1. COMPANY OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. KEY INNOVATION SECTOR
9.4.4. STRATEGIC INITIATIVES
9.4.5. SCOT ANALYSIS
9.5. HARLAN LABORATORIES, INC. (ENVIGO, INC. HOLDING COMPANY)
9.5.1. COMPANY OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC INITIATIVES
9.5.4. SCOT ANALYSIS
9.6. JANVIER LABS
9.6.1. COMPANY OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. SAGE LABS INC(HORIZON DISCOVERY GROUP PLC HOLDING COMPANY)
9.7.1. COMPANY OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC INITIATIVES
9.7.4. SCOT ANALYSIS
9.8. TACONIC BIOSCIENCES
9.8.1. COMPANY OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. KEY INNOVATION SECTOR
9.8.4. STRATEGIC INITIATIVES
9.8.5. SCOT ANALYSIS
9.9. TRANSPOSAGEN BIOPHARMACEUTICALS INC
9.9.1. COMPANY OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. KEY INNOVATION SECTOR
9.9.4. STRATEGIC INITIATIVES
9.9.5. SCOT ANALYSIS
9.10. TRANSVIRAGEN INC.
9.10.1. COMPANY OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.11. HERA BIOLABS INC.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. KEY INNOVATION SECTOR
9.11.4. STRATEGIC INITIATIVE
9.11.5. SCOT ANALYSIS
9.12. ONCODESIGN S.A.
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. KEY INNOVATION SECTOR
9.12.4. STRATEGIC INITIATIVE
9.12.5. SCOT ANALYSIS
9.13. CYAGEN BIOSCIENCES INC.
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. KEY INNOVATION SECTOR
9.13.4. STRATEGIC INITIATIVE
9.13.5. SCOT ANALYSIS
9.14. VIVO BIOTECH LTD.
9.14.1. COMPANY OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. STRATEGIC INITIATIVES
9.14.4. SCOT ANALYSIS
9.15. CLEA JAPAN
9.15.1. COMPANY OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. STRATEGIC INITIATIVES
9.15.4. KEY INNOVATION SECTOR
9.15.5. SCOT ANALYSIS
9.16. TRANSVIRAGEN, INC.
9.16.1. COMPANY OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. STRATEGIC INITIATIVES
9.16.4. KEY INNOVATION SECTOR
9.16.5. SCOT ANALYSIS
9.17. BIOMERE
9.17.1. COMPANY OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. STRATEGIC INITIATIVES
9.17.4. KEY INNOVATION SECTOR
9.17.5. SCOT ANALYSIS
9.18. LABORATORY CORPORATION OF AMERICA HOLDINGS
9.18.1. COMPANY OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. STRATEGIC INITIATIVES
9.18.4. KEY INNOVATION SECTOR
9.18.5. SCOT ANALYSIS
TABLE LIST
TABLE 1 NORTH AMERICA RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 2 BENEFITS OF RAT
TABLE 3 NORTH AMERICA RAT MODEL MARKET BY RAT TYPES 2017-2025 ($ THOUSAND)
TABLE 4 EXAMPLES OF INBRED RAT AND THERE RESEARCH APPLICATIONS
TABLE 5 NORTH AMERICA INBRED RAT TYPE 2017-2025 ($ THOUSAND)
TABLE 6 NORTH AMERICA GENETICALLY ENGINEERED RAT MARKET 2017-2025($ THOUSAND)
TABLE 7 NORTH AMERICA HYBRID RAT MARKET 2017-2025 ($ THOUSAND)
TABLE 8 EXAMPLES OF OUTBRED RAT AND THERE RESEARCH APPLICATIONS
TABLE 9 NORTH AMERICA OUTBRED RAT MARKET 2017-2025 ($ THOUSAND)
TABLE 10 NORTH AMERICA IMMUNE DEFICIT RAT MARKET 2017-2025 ($ THOUSAND)
TABLE 11 NORTH AMERICA SURGICALLY MODIFIED RAT MARKET 2017-2025 ($ THOUSAND)
TABLE 12 NORTH AMERICA RAT MODEL MARKET BY COMPONENTS 2017-2025 ($ THOUSAND)
TABLE 13 NORTH AMERICA RAT MODEL MARKET BY TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 14 NORTH AMERICA NUCLEAR TRANSFER TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 15 NORTH AMERICA MICRO INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 16 NORTH AMERICA EMBRYONIC STEM CELL INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 17 NORTH AMERICA OTHER TECHNOLOGY RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 18 NORTH AMERICA RAT MODEL SERVICES MARKET 2017-2025 ($ THOUSAND)
TABLE 19 NORTH AMERICA RAT MODEL MARKET BY RAT CARE PRODUCTS 2017-2025 ($ THOUSAND)
TABLE 20 NORTH AMERICA RAT FEED MARKET 2017-2025 ($ THOUSAND)
TABLE 21 POPULAR FOODS FOR RAT
TABLE 22 NORTH AMERICA RAT BEDDING MARKET 2017-2025 ($ THOUSAND)
TABLE 23 NORTH AMERICA RAT CAGES MARKET 2017-2025 ($ THOUSAND)
TABLE 24 NORTH AMERICA RAT CARE OTHERS MARKET 2017-2025 ($ THOUSAND)
TABLE 25 NORTH AMERICA RAT MODEL MARKET BY APPLICATION 2017-2025($ THOUSAND)
TABLE 26 NORTH AMERICA DIABETES RAT MODEL MARKET 2017-2025($ THOUSAND)
TABLE 27 NORTH AMERICA ONCOLOGY RAT MODEL MARKET 2017-2025($ THOUSAND)
TABLE 28 NORTH AMERICA IMMUNOLOGY & INFLAMMATION RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 29 NORTH AMERICA OTHER RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 30 NORTH AMERICA RAT MODEL MARKET 2017-2025 ($ MILLION)
TABLE 31 NORTH AMERICA RAT MODEL MARKET BY COUNTRY 2017-2025 ($ MILLION)
TABLE 32 BUDGET AUTHORITY BY ACTIVITY IN THE U.S. 2015-2017 ($ MILLION)
FIGURES LIST
FIGURE 1 NORTH AMERICA RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 2 NUMBER OF EXPERIMENTAL PROCEDURES OF ANIMALS IN U.S. IN 2016
FIGURE 3 TOP COMPANIES BASED ON IN VITRO DIAGNOSTICS REVENUE IN 2016 ($ MILLION)
FIGURE 4 NORTH AMERICA RAT MODEL MARKET BY INBRED RAT TYPE 2017-2025 ($ THOUSAND)
FIGURE 5 NORTH AMERICA RAT MODEL MARKET BY GENETICALLY ENGINEERED RAT 2017-2025 ($ THOUSAND)
FIGURE 6 NORTH AMERICA RAT MODEL MARKET BY HYBRID RAT TYPE 2017-2025 ( $ THOUSAND)
FIGURE 7 NORTH AMERICA RAT MODEL MARKET BY OUTBRED RAT 2017-2025 ($ THOUSAND)
FIGURE 8 NORTH AMERICA RAT MODEL MARKET BY IMMUNE DEFICIENT RAT 2017-2025 ($ THOUSAND)
FIGURE 9 NORTH AMERICA RAT MODEL MARKET BY SURGICALLY MODIFIED RAT 2017-2025 ($ THOUSAND)
FIGURE 10 NORTH AMERICA RAT MODEL MARKET BY TECHNOLOGY 2017-2025 ($ THOUSANDS)
FIGURE 11 NORTH AMERICA RAT MODEL MARKET BY NUCLEAR TRANSFER TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 12 NORTH AMERICA RAT MODEL MARKET BY MICRO INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 13 NORTH AMERICA RAT MODEL MARKET BY EMBRYONIC STEM CELL INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 14 NORTH AMERICA RAT MODEL MARKET BY OTHER TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 15 RAT CARE PRODUCTS BY TYPE 2016 (%)
FIGURE 16 NORTH AMERICA RAT CARE PRODUCT MARKET BY FEED 2017-2025 ($ THOUSAND)
FIGURE 17 NORTH AMERICA RAT CARE PRODUCT MARKET BY BEDDING 2017-2025 ($ THOUSAND)
FIGURE 18 NORTH AMERICA RAT CARE PRODUCT MARKET BY CAGES 2017-2025 ($ THOUSAND)
FIGURE 19 NORTH AMERICA RAT MODEL MARKET BY DIABETES 2017-2025($ THOUSAND)
FIGURE 20 PERCENTAGE OF DIABETES IN WORLD ADULT POPULATION IN 1980, 2015 AND 2040
FIGURE 21 NORTH AMERICA RAT MODEL MARKET BY TOXICOLOGY 2017-2025($ THOUSAND)
FIGURE 22 NORTH AMERICA TOXICOLOGY RAT MODEL MARKET 2017-2025($ THOUSAND)
FIGURE 23 NORTH AMERICA RAT MODEL MARKET BY ONCOLOGY 2017-2025($ THOUSAND)
FIGURE 24 INCREASING COSTS OF ONCOLOGY THERAPEUTICS AND SUPPORTIVE CARE DRUGS ($ BILLION)
FIGURE 25 NORTH AMERICA RAT MODEL MARKET BY IMMUNOLOGY & INFLAMMATION 2017-2025 ($ THOUSAND)
FIGURE 26 NORTH AMERICA RAT MODEL MARKET BY OTHER 2017-2025 ($ THOUSAND)
FIGURE 27 PORTERS 5 FORCE MODEL OF RAT MODEL
FIGURE 28 NORTH AMERICA RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 29 NATIONAL HUMAN GENOME RESEARCH BUDGET, 2017 ($ MILLION)
FIGURE 30 U.S. PHARMACEUTICAL INDUSTRY EXPENDITURE ON R&D 2012-2015 ($ BILLION)
FIGURE 31 U.S. RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 32 FUNDS ALLOCATED FOR RESEARCH ACTIVITIES IN BUDGET 2016
FIGURE 33 CANADIAN PHARMACEUTICAL MARKET 2015 & 2020 ($ BILLION)
FIGURE 34 CANADA RAT MODEL MARKET 2017-2025 ($THOUSAND)
